scorecardresearch
Follow Us:
Saturday, July 11, 2020

Gilead Sciences announces approval of Remdesivir in India for patients with severe Covid-19

A statement issued on Wednesday stated that the regulatory approval is supported by clinical data from the US National Institute of Allergy and Infectious Diseases’

By: Express News Service | Pune | Published: June 4, 2020 12:25:23 am
coronavirus, covid 19, covid 19 in india, Gilead Sciences, Remdesivir, Remdesivir usage for covid 19 patients, indian express news Gilead’s Phase 3 SIMPLE trial in patients with severe manifestations of COVID-19 (Representational Photo)

Gilead Sciences announces approval of Remdesivir in India for patients with severe Covid-19

Gilead Sciences, Inc on Wednesday announced that the Drug Controller General of India (DCGI) has granted regulatory approval of Veklury® (Remdesivir) for treatment of suspected or laboratory-confirmed coronavirus disease (Covid-19) in adults and children hospitalised with severe disease.

A statement issued on Wednesday stated that the regulatory approval is supported by clinical data from the US National Institute of Allergy and Infectious Diseases’ global Phase 3 trial and Gilead’s Phase 3 SIMPLE trial in patients with severe manifestations of COVID-19

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest India News, download Indian Express App.

0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement